Danish drugmaker Novo Nordisk will acquire U.S. drug developer Prothena Corp.’s experimental heart therapy PRX004 in a deal that could be worth up to $1.23 billion, the companies said on July 12.

Array BioPharma spun off some intellectual property and equipment into a new company, Yarra Therapeutics.